Genetic Technologies Limited

ASX:GTG ISIN:AU000000GTG7

Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. Its three-pronged business strategy includes: 1) the global commercialization of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business in Australia; and, 3) the commercialization of its various research and development projects aimed at generating further intellectual property of global commercial significance. 
 
     

查看其它语言版本

新闻

1月7日澳洲股市:对铁矿石价格乐观

🕔1/7/2010 9:30:30 AM 15649

周三澳洲股市收市平淡,受银行股拖累,下午的盘面回吐出早先的涨幅。由于投资者对铁矿石价格乐观,矿业股上涨。收盘时基准指数S&P/ASX200上涨1.6 点,报4925.9 点; 综合指数上涨7.7 点, 或0.15%, 报4947.2点。

阅读全文
###

47,076 公司背景浏览

  • 本页浏览人次: (过去7日: 8) (过去30日: 40) (自发布以来: 8538) 

公司详细信息

    传真
  • (03) 9417 2987 
  • 主要部门
  • 医疗-制药 
  • 支柱产业
  • 生物科技 
  • 主页
  • www.gtg.com.au/

更多新闻纪录

  • 2024/07/19: Change in substantial holding*
  • 2024/07/18: Change in substantial holding*
  • 2024/07/16: S708A Cleansing Notice*
  • 2024/07/16: Application for quotation of securities - GTG*
  • 2024/07/16: Appointment of CFO and Company Secretary*
  • 2024/07/12: Change in substantial holding*
  • 2024/07/09: GeneType to Enter Canadian and New Zealand Markets*
  • 2024/06/28: Resignation of CFO and Company Secretary*
  • 2024/06/28: Business Update - June 2024*
  • 2024/06/25: GeneType identifies 79.5% at risk of serious disease*
*refer to company website